首页> 美国卫生研究院文献>The Journal of Pharmacology and Experimental Therapeutics >Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N′-(2-{8-(26-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-78-dihydropyrido23-d pyrimidin-2-ylamino}ethyl)guanidine (SB706504)
【2h】

Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N′-(2-{8-(26-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-78-dihydropyrido23-d pyrimidin-2-ylamino}ethyl)guanidine (SB706504)

机译:脂多糖刺激的慢性阻塞性肺的抑制作用 地塞米松和p38对疾病巨噬细胞炎症基因表达的影响 丝裂原激活的蛋白激酶抑制剂 N-氰基-N-(2-{8-(26-二氟苯基)-4-(4-氟-2-甲基苯基)-7-氧代-78-二氢吡啶基23-d 嘧啶-2-基氨基}乙基)胍 (SB706504)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

p38 mitogen-activated protein kinase (MAPK) signaling is known to be increased in chronic obstructive pulmonary disease (COPD) macrophages. We have studied the effects of the p38 MAPK inhibitor N-cyano-N′-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]-pyrimidin-2-yl]amino}ethyl)guanidine (SB706504) and dexamethasone on COPD macrophage inflammatory gene expression and protein secretion. We also studied the effects of combined SB706504 and dexamethasone treatment. Lipopolysaccharide (LPS)-stimulated monocyte derived macrophages (MDMs) and alveolar macrophages (AMs) were cultured with dexamethasone and/or SB706504. MDMs were used for gene array and protein studies, whereas tumor necrosis factor (TNF) α protein production was measured from AMs. SB706504 caused transcriptional inhibition of a range of cytokines and chemokines in COPD MDMs. The use of SB706504 combined with dexamethasone caused greater suppression of gene expression (-8.90) compared with SB706504 alone (-2.04) or dexamethasone (-3.39). Twenty-three genes were insensitive to the effects of both drugs, including interleukin (IL)-1β, IL-18, and chemokine (CC motif) ligand (CCL) 5. In addition, the chromosome 4 chemokine cluster members, CXCL1, CXCL2, CXCL3, and CXCL8, were all glucocorticoid-resistant. SB706504 significantly inhibited LPS-stimulated TNFα production from COPD and smoker AMs, with near-maximal suppression caused by combination treatment with dexamethasone. We conclude that SB706504 targets a subset of inflammatory macrophage genes and when used with dexamethasone causes effective suppression of these genes. SB706504 and dexamethasone had no effect on the transcription of a subset of LPS-regulated genes, including IL-1β, IL-18, and CCL5, which are all known to be involved in the pathogenesis of COPD.
机译:已知在慢性阻塞性肺疾病(COPD)巨噬细胞中,p38丝裂原激活的蛋白激酶(MAPK)信号增加。我们已经研究了p38 MAPK抑制剂N-氰基-N'-(2-{[8-(2,6-二氟苯基)-4-(4-氟-2-甲基苯基)-7-oxo-7, 8-二氢吡啶并[2,3-d]-嘧啶-2-基]氨基}乙基)胍(SB706504)和地塞米松对COPD巨噬细胞炎性基因表达及蛋白分泌的影响。我们还研究了SB706504和地塞米松联合治疗的效果。用地塞米松和/或SB706504培养脂多糖(LPS)刺激的单核细胞衍生巨噬细胞(MDM)和肺泡巨噬细胞(AM)。 MDM用于基因阵列和蛋白质研究,而肿瘤坏死因子(TNF)α蛋白的产生是通过AMs进行的。 SB706504导致了COPD MDM中一系列细胞因子和趋化因子的转录抑制。与单独使用SB706504(-2.04)或地塞米松(-3.39)相比,将SB706504与地塞米松联合使用可更大程度地抑制基因表达(-8.90)。 23种基因对两种药物的作用均不敏感,包括白介素(IL)-1β,IL-18和趋化因子(CC主题)配体(CCL)5。此外,第4号染色体趋化因子簇成员CXCL1,CXCL2 ,CXCL3和CXCL8都是 耐糖皮质激素。 SB706504显着抑制LPS刺激 COPD和吸烟者AMs产生的TNFα,具有近乎最大的抑制作用 与地塞米松联合治疗引起的。我们得出结论,SB706504 靶向炎性巨噬细胞基因的子集,当与 地塞米松可有效抑制这些基因。 SB706504和 地塞米松对LPS调节的子集的转录没有影响 包括IL-1β,IL-18和CCL5在内的所有基因 参与COPD的发病机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号